YKL-40 stimulates tumor vascularization via EC and PC/SMC-coordinated angiogenesis and PC/SMC-driven VM, thus pointing to YKL-40 as a new target for cancer therapy. This evidence concerns the gene CHI3L1 and neoplasm.